Pharmafile Logo
Pharmafocus logo
Advanced Search

AbbVie acquires Syndesi Therapeutics

March 7, 2022
Sales and Marketing

Syndesi Therapeutics has been acquired by AbbVie in a deal worth a potential $1 billion.Syndesi was created in 2018 as …

News

India: approval for drug treating CKD-associated anaemia

March 7, 2022
Sales and Marketing

Zydus Lifesciences received approval from the Drugs Controller General of India (DCGI) for its new drug application for Oxemia (Desidustat). …

News

Phase III trial into nirsevimab for RSV treatment yields positive results

March 4, 2022
Medical Communications

The latest results from Sanofi and AstraZeneca’s Phase III trial nirsevimab support the vaccine’s ability to protect all infants from …

News

Median Technologies iBiopsy Lung Cancer Screening Software

March 4, 2022
Medical Communications

Median Technologies has announced that the company has filed a regulatory submission to the FDA for its iBiopsy Lung Cancer …

News

Promising treatment targeting 40% mortality Candida infection

March 4, 2022
Medical Communications

A Promising Innovation Medicine (PIM) designation has been awarded to rezafungin by the MHRA, for the treatment of invasive candidiasis. …

News

Anti-inflammatory baricitinib is a life-saving COVID-19 drug

March 4, 2022
Medical Communications

UK experts say they have identified another life-saving drug that can alleviate COVID-19 illness. The anti-inflammatory baricitinib is usually used …

News

Risk of hospitalisation five times higher with J&J

March 3, 2022
Business Services, Medical Communications

A study published in Jama Network Open has revealed that Johnson & Johnson’s coronavirus vaccine was far less effective at …

News

FDA grants breakthrough therapy designation to RSV vaccine

March 3, 2022
Business Services, Medical Communications

The FDA has granted a Breakthrough Therapy Designation to Pfizer’s respiratory syncytial virus (RSV) vaccine candidate, for the prevention of …

News

WHO recommends Merck’s COVID-19 pill

March 3, 2022
Business Services, Medical Communications

WHO have recommended Merck’s pill, molnupiravir, for the treatment of COVID-19 in patients in high risk groups, such as the …

News

First smart connected insulin pens made available on NHS

March 2, 2022
Research and Development

Today, Novo Nordisk will launch the first smart connected insulin pens to be made available on NHS prescription. The pens, …

News

Fera Pharmaceuticals receives Orphan Drug Designation from FDA for sickle cell treatment

March 2, 2022
Research and Development

The FDA has granted an Orphan Drug Designation for naproxcinod for the treatment of sickle cell disease, which affects an …

News

HPV vaccines could mean only one smear test a lifetime

March 2, 2022
Research and Development

A leading scientist has said that women who have the HPV vaccine may need only one smear test to prevent …

News

FDA share new trial guidelines to further cancer therapy development

March 2, 2022
Research and Development

The FDA has issued three recommendations to industry for clinical trials, to support US President Joe Biden’s relaunch of the …

News

Moderna faces lawsuit over COVID-19 vaccine

March 1, 2022
Manufacturing and Production

Moderna has been accused of ‘hijacking’ technology from two smaller biotech firms – Arbutus Biopharma and Genevant Sciences – to …

News

ELUNATE receives commercial approval in Macau

March 1, 2022
Manufacturing and Production

HUTCHMED has received approval to market fruquintinib (ELUNATE in China), a selective and potent oral inhibitor of vascular endothelial growth …

News

FDA approves CAR-T therapy for multiple myeloma

March 1, 2022
Manufacturing and Production

The FDA gas approved a therapy developed by J&J and its partner Legend Biotech, to treat relapsed or refractory multiple …

News

First oral diabetes treatment approved in Europe for use during pregnancy

March 1, 2022
Manufacturing and Production

Merck has announced an extension to the label for metformin products in the EU – glucophage (metformin hydrochloride immediate release), …

News

Potential breakthrough trial for rare disease Hunter syndrome

February 28, 2022
Sales and Marketing

Actigen has initiated a clinical development programme for GNR-055, a potentially breakthrough treatment for the debilitating, life-limiting, rare disease mucopolysaccharidosis …

News

Phase III data show Dupixent reduced itch in chronic spontaneous urticaria patients

February 28, 2022
Sales and Marketing

Results from a Phase III trial have revealed that adding Dupixent (dupilumab) to standard-of-care antihistamines significanty reduced itch and hives …

News

Urgent need to address mental health crisis among kidney patients

February 28, 2022
Sales and Marketing

Kidney Research UK has released their findings from a survey of 1,000 kidney disease patients in the UK, revealing the …

News
The Gateway to Local Adoption Series

Latest content

Complement Therapeutics’ geographic atrophy treatment receives FDA Fast Track designation

January 22, 2026

PSI appoints David Allen as Country Manager for Canada

January 22, 2026

Qureight appoints Steven Bishop as Chief Medical Officer

January 21, 2026

Pierre Fabre Laboratories and Iktos announce oncology collaboration

January 21, 2026

Qureight appoints Rebecca Simmons as Chief Operating Officer

January 20, 2026